Semaglutide Research: Mechanism, Trials & the Evidence, Cited
Start here
This is the deep read of the Semaglutide research record, organized so the strongest evidence runs first. The short orientation: semaglutide is a GLP-1 receptor agonist (a long-acting copy of a gut hormone) with one of the largest trial portfolios in modern metabolic medicine — tens of thousands of participants across the SUSTAIN (diabetes injection), PIONEER (diabetes tablet), and STEP (weight) programs, plus dedicated outcome trials for the heart (SELECT), the kidneys (FLOW), and the liver (ESSENCE) [12]. The headline that anchors this site is cardiovascular: a 20% reduction in major adverse cardiovascular events in people with heart disease and obesity [3]. Below, each major finding gets its own section, every number is cited, and the open questions are marked as open rather than filled in.
What is semaglutide
Semaglutide is a 31-amino-acid acylated analogue of human GLP-1, sharing about 94% of its sequence with the natural hormone [12]. The endogenous hormone GLP-1 is released from the gut after eating and does three useful things: it nudges the pancreas to release insulin only when blood sugar is high, it tells the pancreas to ease off the opposing hormone glucagon, and it slows the stomach and signals fullness to the brain [12]. Semaglutide mimics all of that, but lasts about a week instead of two minutes. The drug class is the incretin mimetics; its formal designation is a GLP-1 receptor agonist [12].
Semaglutide peptide chemistry
As a semaglutide peptide, the molecule earns its once-weekly schedule through two deliberate modifications [12]. At position 8, the natural alanine is swapped for alpha-aminoisobutyric acid (Aib), a non-standard amino acid that blocks cleavage by DPP-4, the enzyme that normally degrades GLP-1 within minutes [12]. The single remaining lysine is decorated with a C18 fatty di-acid chain through a spacer; that lipid tail binds reversibly but tightly to albumin, the most abundant blood protein, which shields the peptide from kidney clearance and metabolism [12]. The result is an elimination half-life of roughly one week and steady drug levels that persist for about five weeks after the last dose [12].
The cardiovascular evidence (the headline)
This is the strongest part of the record, so it leads. In SELECT, 17,604 adults with established cardiovascular disease and a BMI of 27 or higher, none with diabetes, were randomized to once-weekly semaglutide 2.4 mg or placebo. The primary composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke fell by 20% (HR 0.80; 95% CI 0.72-0.90; P<0.001) [3]. A 2024 analysis confirmed the MACE benefit was independent of baseline glycemia and weight category [13].
The diabetes signal preceded it. In SUSTAIN-6, once-weekly semaglutide (0.5 or 1.0 mg) reduced the same composite by 26% in 3,297 people with type 2 diabetes at high cardiovascular risk (HR 0.74; 95% CI 0.58-0.95) [2]. For the oral form, PIONEER 6 showed once-daily oral semaglutide was noninferior to placebo for major adverse cardiovascular events in high-risk type 2 diabetes, with numerically lower cardiovascular-death and all-cause-death rates [8]. And in STEP-HFpEF, semaglutide 2.4 mg improved heart-failure symptoms and physical limitations and produced greater weight loss than placebo in obesity-related heart failure with preserved ejection fraction [9] — the focus of the semaglutide heart failure page.
Semaglutide weight loss
On semaglutide weight loss, the anchor trial is STEP 1: a mean body-weight change of -14.9% versus -2.4% with placebo at week 68 in 1,961 adults with overweight or obesity and no diabetes [1]. Exploratory STEP 1 and STEP 4 analyses found semaglutide improved waist circumference, blood pressure, lipids, glycemia, and inflammatory markers alongside the weight change [10]. The mechanism behind the weight loss is central and is detailed on how does semaglutide work; the durability caveat — substantial regain after stopping — is covered on the effects page.
Beyond the heart: kidneys and metabolism
The benefit extends past the cardiovascular endpoint. In FLOW, 3,533 people with type 2 diabetes and chronic kidney disease on once-weekly semaglutide 1.0 mg had a 24% lower risk of major kidney-disease events — kidney failure, a 50% or greater drop in eGFR, or kidney/cardiovascular death (HR 0.76; 95% CI 0.66-0.88) [7]. On the diabetes side, SUSTAIN FORTE showed once-weekly semaglutide 2.0 mg lowered HbA1c more than the 1.0 mg dose, which supported approval of the higher diabetes dose [20]. A pharmaceutical-sciences review pulls the efficacy, pharmacokinetics, and dosing across indications together in one place [12].
Semaglutide vs tirzepatide
On semaglutide vs tirzepatide, there is now a head-to-head. In SURMOUNT-5, 751 adults with obesity were randomized to one agent or the other; tirzepatide produced greater mean weight loss at 72 weeks (-20.2% vs -13.7%; difference statistically significant, P<0.001) [21]. A 2025 modeling paper projected comparative 10-year cardiovascular-risk differences between the two agents [22]. The plain read: on weight, the head-to-head favored tirzepatide by about 6.5 percentage points; on hard cardiovascular outcomes, semaglutide is the one with the large dedicated event trial behind it [3].
Semaglutide side effects
The semaglutide side effects record is dominated by the gut. A dedicated safety review concluded an overall favorable risk/benefit profile, with mostly mild-to-moderate transient gastrointestinal effects — nausea in roughly one-third of patients — plus an increased risk of biliary disease, and pancreatic and thyroid-cancer signals for which firm conclusions cannot yet be drawn because of low incidence [5]. Diabetic-retinopathy complications were more frequent in SUSTAIN-6 among those correcting blood sugar rapidly (HR 1.76) [2]. The full, plain-English side-effect and safety breakdown — and the labeled community reports — live on the effects page.
Compounded semaglutide
Compounded semaglutide is the record's biggest real-world caveat. During the federally declared shortage, compounding pharmacies were permitted to produce semaglutide; the FDA documented dosing errors, adverse events requiring hospitalization, and products with unverified or non-pharmaceutical active ingredients [5]. After the shortage was declared resolved in 2025, the compounding pathways were curtailed, leaving ongoing regulatory and telehealth uncertainty [12]. Compounded or non-pharmaceutical material sits outside the approved-product evidence base that the trials above are built on.
What the record does not yet settle
Honesty section. The thyroid-cancer boxed warning rests on rodents at high exposures; human data have not established a clear medullary thyroid carcinoma signal [6][5]. Pancreatic-cancer signals remain unconfirmed owing to low numbers [5]. Neuropsychiatric reports have appeared in monitoring databases and remain under surveillance, with controlled trials not establishing a causal link [5]. And the durability question is settled in the wrong direction for anyone hoping for a cure: stopping brings substantial regain [19]. These are open or cautionary, and this site marks them that way rather than rounding them up to certainty.